Lessons learnt for public health from the Ebola outbreak in West Africa – how to improve preparedness and response in the EU for future outbreaks
The aim of this conference was to identify learning points arising from the Ebola outbreak in 2014 and 2015 in West Africa.
Reinforcing the fight against Ebola in Guinea
As reinforcement to help fight Ebola in the affected West African countries, the European Centre for Disease Prevention and Control is deploying four teams of French-speaking epidemiologists to support surveillance and response in Guinea.
ECDC call for epidemiologists to join its Ebola response teams in Guinea
Despite a dramatic improvement of the epidemiological situation in Guinea in 2015, the elimination of human transmission of the Ebola virus will require sustained efforts over the next few months. ECDC will continue deploying experts to Guinea to contribute to the field work related to surveillance and response activities, under the World Health Organization's Global Outbreak Alert and Response Network (GOARN) umbrella.
High level conference on “Ebola: From Emergency to Recovery”: response so far and planning the recovery
On March 3 2015, the European Union organised a high-level conference on the Ebola epidemic. The purpose was two-fold: first, to take stock of the ongoing emergency response and adapt it to the evolving situation on the ground, leading to eradication of the disease; second, to plan for the long term and support the recovery and resilience of the affected countries, including the development of their health systems.
ECDC in the field (Ebola missions to West Africa)
As reinforcement to help fight Ebola in the affected West African countries, during the 2013-2016 outbreak, the ECDC deployed epidemiologists to support surveillance and response in Guinea.
Ebola treatment trial: two drugs identified as more effective
Two out of the four drugs tested in a multi-drug randomised control trial have been found more effective in treating Ebola, the World Health Organization announced on Monday. The Data and Safety Monitoring Board, an independent body that has been reviewing interim safety and efficacy data, has therefore recommended that the study be stopped and that all future patients be randomized to receive either REGN-EB3 or mAb114, in what is being considered an extension phase of the study.